A critical review of published economic modelling studies in depression

PharmacoEconomics

Volumn 17, Issue 6, 2000, Pages 555-583

  Jones, Michael T ^a,c   Cockrum, Paul C ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Alcon Research Inc   (United States)

^c M3 C19 Medical School Building   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; FLUOXETINE; IMIPRAMINE; MAPROTILINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DEPRESSION; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; HUMAN TISSUE; INCIDENCE; MALE; META ANALYSIS; MULTICENTER STUDY; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW;

EID: 0034045698     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017060-00003     Document Type: Review

References (47)

1. 1. Greenberg PE, Stiglin LE, Finkelstein SN. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54:405-18
2. 2. Stoudemire A, Frank R, Hedemark N, et al. The economic burden of depression. Gen Hosp Psychiatry 1986; 8: 387-94
3. 3. Rice DP, Miller LS. The economic burden of affective disorders. Br J Psychiatry 1995; 166: 34-42
4. 4. West R. Depression. London: Office of Health Economics, 1992
5. 5. Canadian Coordinating Office for Health Technology Assessment. Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part 1. Evaluation of the clinical literature. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997
6. 6. Canadian Coordinating Office for Health Technology Assessment. Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part 2. The cost-effectiveness of SSRIs in the treatment of depression. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997
7. 7. Nuijten MJ, Hardens M, Souetre E. A Markov process analysis comparing the cost efficacy of maintenance therapy with citalopram versus standard therapy in major depression. Pharmacoeconomics 1995; 8: 159-68
8. 8. Hatziandreu EJ, Brown RE, Revicki DA, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics 1994; 5: 249-64
9. 9. Revicki DA, Brown RE, Keller MB, et al. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 1997; 58: 47-58
10. 10. Bentkover JD, Feighner JP. Cost analysis of paroxetine versus imipramine in major depression. Pharmacoeconomics 1995; 8: 223-32
11. 11. Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br J Psychiatry 1991; 159: 394-8
12. 12. Simon GE, Von Korff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275: 1897-902
13. 13. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997
14. 14. Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee. Canberra: Commonwealth Department of Human Services and Health, 1995
15. 15. Anton SF, Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone. Psychopharmacol Bull 1995; 31: 249-58
16. 16. Hylan TR, Kotsanos JG, Anderson JS, et al. Comparison of a decision analytical model with results from a naturalistic economic clinical trial: an application to evaluating alternative antidepressants. Am J Manag Care 1996; 2: 1211-23
17. 17. Einarson TR, Arikian SR, Sweeny S, et al. A model to evaluate the cost-efficacy of oral therapies in the management of patients with major depressive disorders. Clin Ther 1995; 17: 136-53
18. 18. Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics 1997; 12: 286-96
19. 19. Kind P, Sorensen J. Modeling the cost-efficacy of the prophylactic use of SSRIs in the treatment of depression. Int Clin Psychopharmacol 1995; 10: 41-8
20. 20. Revicki DA, Brown RE, Palmer W, et al. Modeling the cost efficacy of antidepressant treatment in primary care. Pharmacoeconomics 1995; 8: 524-40
21. 21. Drug Topics Red Book. Montvale (NJ): Medical Economics Company, 1998
22. 22. Frank E, Kupfer DJ, Wagner EF, et al. Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression: contributing factors. Arch Gen Psychiatry 1991; 48: 1053-9
23. 23. Klerman GL, Weissman MM. The course, morbidity and costs of depression. Arch Gen Psychiatry 1992; 49: 831-4
24. 24. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986; 143: 18-23
25. 25. Agency for Health Care Policy and Research (AHCPR). Clinical practice guidelines for depression ('depression in primary care' guidelines), 1998. Available from: http://www.ahcpr. gov/clinic/medtep/resource.htm [Accessed 2000 Apr 13]
26. 26. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9: 47-53
27. 27. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985; 5: 157-77
28. 28. Medical Information Management Service (MIMS) [1994 data]. London: MediMedia International, 1994
29. 29. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medication. J Affect Disord 1998; 48: 25-36
30. 30. Stoner SC, Marken PA, Watson WA, et al. Antidepressant overdoses and resultant emergency department services: the impact of SSRIs. Psychopharmacol Bull 1997; 33: 667-70
31. 31. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991; 52: 28-34
32. 32. Copley-Merriman C, Lair TJ. Valuation of medical resource units collected in health economic studies. Clin Ther 1994; 16: 553-68
33. 33. SMLTREE generic software package, version 2.9. Roslyn (NY): Jim Hollenberg, 1989
34. 34. Physicians desk reference (PDR). Montvale (NY): Medical Economics Company, 1997
35. 35. Celexa™ (citalopram HBr) [package insert]. St Louis (MO): Forrest Laboratories, Inc., 1998
36. 36. Department of Health and Human Services. Approved drug products with therapeutic equivalence evaluations. 17th ed. Washington (DC): Department of Health and Human Services, Public Health Service, FDA, Division of Database Management, 1997
37. 37. Incidence and prevalence database (IPD), 1988. Available from: http://open.academic.N2K.com/p/P0465AA.htm [Accessed 2000 Apr 13]
38. 38. Kessler RC, McGonagle KA, Nelson CB, et al. Sex and depression in the National Comorbidity Survey II: cohort effects. J Affect Disord 1994; 30: 15-26
39. 39. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217-22
40. 40. Mueller TI, Leon AC. Recovery, chronicity, and levels of psychopathology in major depression. Psychiatr Clin North Am 1996; 19: 85-102
41. 41. Keller MB, Shapiro RW, Lavori PW, et al. Relapse in major depressive disorder: analysis with the life table. Arch Gen Psychiatry 1982; 39: 911-5
42. 42. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683-7
43. 43. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995; 310: 1433-8
44. 44. Medispan™ database. Available from: http://www.medispan.com
45. 45. Price Probe™ database. Available from: http://www. firstdatabank.com/drug/nddf_product_line/software_products/ price_probe/price_probe.htm
46. 46. First Databank database. Available from: http://www. firstdatabank.com
47. 47. Buxton MJ, Drummond MF, Van Hout BA, et al. Modeling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217-27